Arcturus Therapeutics Holdings financials
$13.70−5.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.1M | $7.2M | $17.2M | $28.3M | $29.4M | $22.8M | $41.7M | $49.9M | $38.0M | $30.9M | $45.1M |
| Gross profit | $3.0M | $2.1M | $7.2M | $17.2M | $28.3M | $29.4M | $22.8M | $41.7M | $49.9M | $38.0M | $30.9M | $45.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$25.5M | -$28.9M | -$31.3M | -$16.5M | -$11.6M | -$16.8M | -$33.4M | -$10.7M | -$21.1M | -$30.4M | -$18.3M | -$19.3M |
| Net income | -$23.8M | -$27.0M | -$29.1M | -$13.4M | -$9.2M | -$14.1M | -$30.0M | -$6.9M | -$17.2M | -$26.8M | -$11.7M | -$16.2M |
| Net margin | −803.8% | −1308.3% | −404.1% | −78.4% | −32.4% | −47.9% | −131.8% | −16.6% | −34.5% | −70.5% | −37.9% | −35.9% |
| Diluted EPS | $-0.84 | $-0.95 | $-1.03 | $-0.49 | $-0.34 | $-0.52 | $-1.11 | $-0.26 | $-0.64 | $-1.00 | $-0.45 | $-0.61 |
| EBITDA | -$24.9M | -$28.3M | -$30.6M | -$15.7M | -$10.8M | -$16.0M | -$32.6M | -$9.8M | -$20.2M | -$29.5M | -$18.3M | -$18.5M |
| Operating cash flow | -$19.9M | -$19.4M | -$16.2M | -$17.2M | -$5.8M | -$35.1M | -$284.0K | -$23.8M | -$30.1M | -$5.6M | -$629.0K | -$32.4M |
| Free cash flow | -$19.9M | -$19.4M | -$16.3M | -$17.3M | -$5.8M | -$35.3M | -$284.0K | -$23.8M | -$30.5M | -$5.8M | -$1.5M | -$33.4M |
| Diluted shares | 28.4M | 28.4M | 28.1M | 27.2M | 27.1M | 27.1M | 27.1M | 27.1M | 27.0M | 26.9M | 26.2M | 26.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $191.5M | $211.4M | $230.9M | $180.4M | $196.5M | $216.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.0M |
| Total assets | $224.3M | $245.4M | $271.1M | $282.3M | $309.3M | $331.8M |
| Total liabilities | $52.5M | $54.0M | $57.2M | $57.8M | $78.2M | $98.0M |
| Shareholders' equity | $171.8M | $191.4M | $214.0M | $224.6M | $231.1M | $233.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology